[PRESS RELEASE] – TORONTO, July 16, 2026 – Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced the introduction of its proprietary QUIX™-powered rapid-onset medical cannabis portfolio, with initial SKUs to be available across Canadian medical cannabis channels starting the third quarter of 2026 and additional SKUs planned for later in the year.
The new portfolio reflects the company’s continued focus on supporting the evolution of medical cannabis through standardized, accurately dosed and non-combustible product formats. The introduction represents an important milestone in Avicanna’s strategy to translate its scientific platform and proprietary drug delivery technologies into differentiated, evidence-based cannabinoid products. The initial SKUs are expected to become available nationwide through Canadian medical cannabis channels, including Avicanna's MyMedi.ca medical cannabis care platform in August.
Commercializing Avicanna’s Proprietary QUIX Nanotechnology Platform
QUIX is Avicanna’s proprietary, evidence-based, self-emulsifying drug delivery technology developed to address inherent challenges associated with cannabinoid delivery, including poor water solubility, low and variable bioavailability, and delayed onset of effects. The liquid technology produces nano-sized cannabinoid droplets designed to provide rapid onset, enhanced cannabinoid absorption and consistent product performance. The technology has also been optimized for long-term cannabinoid stability and improved sensory characteristics.
Leveraging years of research and development, and real-world experience, Avicanna has incorporated QUIX nanotechnology into a portfolio of more than 20 proprietary SKUs, including nano drops, soft chews, capsules and beverages containing various concentrations and combinations of THC, CBG and CBN. Alongside Canadian commercialization, the company plans to pursue international commercialization opportunities through finished-products exports and licensing partnerships.
Supporting Treatment Optimization and the Evolution of Cannabinoid-Based Medicine
Through the introduction of the QUIX-powered portfolio, Avicanna aims to provide patients and health care practitioners with additional options that may support individualized treatment approaches and reduce reliance on combustible cannabis products. Complemented by patient support and health care practitioner oversight, the company aims to support treatment optimization and responsible cannabinoid use.
Aras Azadian, CEO of Avicanna, said, “The commercialization of products powered by QUIX nanotechnology represents another important milestone in our strategy of translating Avicanna’s scientific platform and proprietary technologies into differentiated, evidence-based commercial products. We believe QUIX strengthens our ability to support treatment optimization and the continued evolution and integration of cannabinoid-based medicine into patient care, while creating additional opportunities to commercialize and scale Avicanna’s intellectual property.”
